Navigation Links
Resverlogix Completes Patient Recruitment for ASSERT Trial
Date:2/8/2010

Full enrollment occurs five months ahead of schedule

TSX Exchange Symbol: RVX

CALGARY, Feb. 8 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today the completion of patient enrollment in the Phase 2 clinical study of its lead drug RVX-208. "The completion of enrollment for our Phase 2 ASSERT trial, a full 5 months ahead of our original schedule, is a very exciting achievement for our staff and our collaborators at the Cleveland Clinic. At this rate we could be seeing the final dosed patient in May of 2010. In the second half of 2010, we look forward to being able to share the results from the trial, which will mark yet another major milestone in the development of our oral therapeutic for the treatment of atherosclerosis," explained Donald J. McCaffrey, President and CEO of Resverlogix Corp.

Once completed, the randomized, double-blind, placebo-controlled, multi-centered US study will have administered RVX-208 to approximately 280 patients with stable coronary artery disease for a period of 13 weeks. The primary objective of this study is to determine if RVX-208 will produce an increase in plasma apolipoprotein A-I (ApoA-l) levels compared to placebo group after three months of dosing. The secondary objectives are to examine the safety and tolerability of RVX-208, to compare the dose and time response relationships for ApoA-l over time as well as to examine key reverse cholesterol markers involved with HDL functionality.

In other news today, Donald J. McCaffrey will be providing an updated corporate overview during the BIO CEO & Investor conference. Mr. McCaffrey's presentation will take place in the Basildon room at the Waldorf-Astoria, New York City, from 4:00 pm - 4:25 pm EST.


'/>"/>
SOURCE Resverlogix Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Arthur J. Higgins, CEO of Bayer HealthCare, Appointed to Resverlogix Board of Directors
2. Resverlogix Presenting at Biotech Showcase
3. Resverlogix Commences Phase 2 Atherosclerosis Clinical Trial
4. Resverlogix Updates Shareholders on Accelerated Clinical Trial Plan
5. Resverlogix Appoints A. Brad Cann as Chief Financial Officer
6. Resverlogix RVX-208 Second Clinical Trial Demonstrates Success on Key Reverse Cholesterol Transport Markers
7. Resverlogix Phase 1b/2a Study Meets Primary Endpoint
8. Resverlogixs Success in Inflammation Program Results in 2 Patents Filed
9. Resverlogix Provides Quarterly Update
10. Resverlogix Board of Directors Update
11. Resverlogix Advances to Second Arm of Phase 1b/2a Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)... a chain of carbon atoms can turn it from ... University scientists. , Stretching the material known as carbyne ... by just 3 percent can begin to change its ... mechanically activated nanoscale electronics and optics. , The finding ... appears in the American Chemical Society journal Nano ...
(Date:7/21/2014)... 21, 2014 Sleep disturbances such ... closely correlated with depression. According to a study ... "About three quarters of depressed patients have insomnia ... of young depressed adults and 10% of older ... cause huge distress, have a major impact on ...
(Date:7/18/2014)... , July 18, 2014  Neogen Corporation (Nasdaq: ... , Neogen,s chief operating officer and president, has resigned, ... work as a consultant going forward on special projects. ... has been in this position since September 2013. On ... James Herbert , who has been Neogen,s chief ...
(Date:7/18/2014)... Cambridge, MA (PRWEB) July 18, 2014 ... in Budapest with US offices in Cambridge, MA, ... a combination Assay and Software product that leverages ... use on the Illumina® MiSeq sequencing platform. The ... with The Children’s Hospital of Philadelphia (CHOP) and ...
Breaking Biology Technology:Carbyne morphs when stretched 2Carbyne morphs when stretched 3Open Label Data on Enhanced Sleep Released by JayMac Pharmaceuticals, LLC 2Open Label Data on Enhanced Sleep Released by JayMac Pharmaceuticals, LLC 3Omixon Launches Holotype HLA for NGS-based HLA Genotyping 2Omixon Launches Holotype HLA for NGS-based HLA Genotyping 3
... , , , Multiporator , , , , , ... Transfection Protocol , Protocol No. 4308 915.026 11/2001 , ... , , , ... line), , , ...
... , , , Multiporator / Electroporator 2510 , , , , , ... Transformation Protocol , Protocol No. 4308 915.525 01/2002 , ... , , , ... , Cell type , Bacteria, gram positive, ...
... Multiporator / Electroporator 2510 , , , , , , , ... Protocol No. 4308 915.540 07/2002 , , ... , , Microorganism , ... Cell type , Bacteria, gram positive, , ...
Cached Biology Technology:Sp20-Ag14 2Sp20-Ag14 3Nocardia asteroides 2Pediococcus spp. 2
(Date:7/21/2014)... Irvine, Calif., July 21, 2014 Dysfunction in ... about 2,000 genes in the brain,s prefrontal cortex ... complex neuropsychiatric disorders, such as schizophrenia, according to ... gene activity in brain cells that receive this ... deficiencies can affect a variety of behavioral and ...
(Date:7/21/2014)... satellites detected 154 hotspots in areas across Riau province ... had increased again following a decline in rainfall. ... far higher than what had been reported one day ... hotspots were scattered in six regencies and municipalities, most ... and the related haze it creates could potentially spread ...
(Date:7/21/2014)... change, due to greenhouse gasses emitted by livestock. New ... and that beef cattle are responsible for far more ... is published by Climactic Change . , ... to climate change. It is released by vehicles, industry, ... greenhouse gas totals. But methane and nitrous oxide are ...
Breaking Biology News(10 mins):UCI researchers find epigenetic tie to neuropsychiatric disorders 2Climate: Meat turns up the heat 2
... with a large-scale "geoengineering" fix, such as having a ... or building tens of millions of chemical filter systems ... But Richard Turco, a professor in ... a member and founding director of UCLA,s Institute of ...
... Rochester have designed a gene that produces a ... in healthy cells., The findings may help address ... ability to specifically and effectively target cancer cells. ... to insert "self-destruct" codes into the modified gene, ...
... Commonwealth University Life Sciences survey shows that eight in 10 ... who want it, and 54 percent say that the benefits ... about genetic research are varied with a plurality of 38 ... known about how to conduct such research safely. About three ...
Cached Biology News:No quick or easy technological fix for climate change, researchers say 2No quick or easy technological fix for climate change, researchers say 3No quick or easy technological fix for climate change, researchers say 4Modified gene targets cancer cells a thousand times more often than healthy cells 2Modified gene targets cancer cells a thousand times more often than healthy cells 3VCU survey: US public supports genetic research, testing and government spending on research 2VCU survey: US public supports genetic research, testing and government spending on research 3
... CHEMICON's Cell Transformation Detection Assay is an ... is considered the most stringent assay for ... this assay, cells (pre-treated with carcinogens or ... in soft agar medium for 21-28 days. ...
The Saturn 2200 answers your GC/MS questions with the CP-3800 GC and the 2000 Series Ion Trap MS! These components create a platform for the worlds most versatile GC and flexible MS. Both deliver une...
... Kit uses a simplified procedure and streamlines ... The kit is based on the three ... and sodium bisulfite where cytosine is converted ... innovative in-column desulphonation reaction eliminates several precipitation ...
... Invitrogen makes blotting of E-PAGE Gels ... pre-cut fiber blotting pad and several types ... perfectly fit 8.6 cm x 13.5 cm ... PVDF membranes are designed for western transfer ...
Biology Products: